Ajinomoto Althea expanding GMP production at California facility

Syringe
Japanese CDMO Ajinomoto Althea is expanding its GMP production offerings at its recently completed high-potency products manufacturing facility in San Diego.

Japanese CDMO Ajinomoto Althea is expanding its GMP production offerings at its recently completed high-potency products manufacturing facility in San Diego.

The plant, which offers process development and analytical services, is scheduled to begin GMP bioconjugation and complex formulation in November, the company said. The new facility is located about three miles from Althea’s current operations. Full operations with the addition are expected to begin by late 2018.

Additionally, the company announced it secured its first manufacturing contract for the new facility. Terms of the deal were not disclosed.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“There is limited capacity in the marketplace and customers are eager to secure availability in a state-of-the-art facility,” Jason Brady, Althea’s senior director and head of business, said in a statement.

RELATED: Ajinomoto Althea adding ADC, HPAPI manufacturing with new California plant

The Japanese conglomerate Ajinomoto bought Althea in 2013 for an undisclosed price. The company announced in 2015 it would retrofit its 57,000-square-foot facility to add capabilities to handle bioconjugation, formulation, purification, quality control, and aseptic fill finish including lyophilization.

In recent years, there has been a push by CDMOs to add ADC and HPAPI manufacturing capabilities. Swiss contract manufacturer Lonza announced several years ago a $15.2 million investment in its plant in Visp, Switzerland, to add to its ADC capacity, while French contract manufacturer Novasep invested about $3.7 million in a plant in LeMans, France, for the same purpose. Fujifilm and Indian manufacturer Piramal teamed up to develop and manufacture ADCs as well.

Suggested Articles

As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.

What challenges continue to plague the pharmaceutical industry for almost a decade? Check out this remarkable innovation in glass science that may be the…

WuXi Biologics says its plant in Wuxi, China, has gotten the go-ahead from the FDA to make HIV drug Trogarzo for TaiMed Biologics.